Welcome to Xediton
Meeting the Needs of Patients, Physicians & Partners
Xediton Pharmaceuticals is a reputable pharmaceutical company with headquarters in Oakville, Ontario. We demonstrate a strong commitment to addressing the needs of physicians, business partners and patients. Xediton strives to provide effective and safe medications to improve the lives of Canadians while fostering strong partnerships within the healthcare community.
Prescription
Medical Device
Non-Prescription
Our Mission
We develop products and services that add value to patients’ lives. We form long-term and trusted relationships.
We aim to be the partner-of-choice for our patients, physicians, business partners and strategic alliances.
Business Development
In order to introduce cutting-edge, unique, therapeutic drugs to Canada to improve the lives of Canadians, we are committed to forming long lasting international partnerships with global pharmaceutical and biomedical companies.
Our management team conducts diligent business development activities while devoting significant corporate resources to strengthen the partnerships and alliances with our international partners.
Our Therapeutic Areas
Our core business areas focus on prescription, medical devices and Over the Counter (OTC) products. Through collaboration with multiple organizations worldwide, Xediton has had the opportunity to partner with some of the largest pharmaceutical companies in Europe to bring products to Canada within a broad range of therapeutic areas including:
- Oncology
- Infectious Diseases
- Immunology
- Urology
- Pain
- Fertility
- Cardiovascular
- Neurological
- Anti-Infectives
Frequently Asked Questions
Leave Blank
How do I report a product issue or complaint with a product?
Please contact our customer service department via email at customerservice@xediton.com or call 1-888-XEDITON (933-4866)
How can I learn about the availability or order certain Xediton products?
Xediton’s products are available through all major Canadian wholesalers.
How can I access a product’s monograph?
Please visit the product section of our website by clicking here
Are you a patient with a medical question?
For questions regarding your personal health conditions, please consult your health care professional.
How can a health care professional acquire samples of a Xediton product?
To obtain samples for your medical establishment, please contact the representative servicing your area. You may obtain the details of your representative by calling the Xediton Customer Service team at 1-888-XEDITON (933-4866)
How can I find a Xediton sales representative that services my area?
Please contact our customer service department via email at customerservice@xediton.com or call 1-888-XEDITON (933-4866) and our customer service team will connect you with a local sales representative
I have experienced an adverse event. What should I do?
If you have experienced an adverse event, please contact your health care professional immediately and then report the event to us by calling 1-888-XEDITON (933-4866) or email our drug safety team at drugsafety@xediton.com
Please report all safety information even if the details are incomplete:
- Name of the product, including dose, strength, frequency and lot number
- A description of the product complaint or side effect associated with the product, including all symptoms
- Your name and contact information (optional)
- Information about the person who experienced the side effect (e.g., initials, date of birth, gender)
How do I obtain pricing information on a Xediton product?
Please contact our customer service department via email at customerservice@xediton.com or call 1-888-XEDITON (933-4866)
News & Press Releases
Melinta Therapeutics and Xediton Pharmaceuticals Announce Licensing Agreement to Commercialize Anti-Infective Products in Canada
Melinta Therapeutics, LLC (Melinta) and Xediton Pharmaceuticals Inc (Xediton) announced they have entered into an exclusive commercialization and licensing agreement for BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin) and VABOMERE® (meropenem and vaborbactam), four novel anti-infective products. Under the terms of the agreement, Xediton is responsible for the registration and commercialization